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Background
Cannabinoids and the endocannabinoid system play an
important role the protection against inflammation and
cancer. O-1602, a synthetic cannabinoid with antiinflam-
matory properties, has little affinity to classical cannabi-
noid receptors but shows cannabinoid-like effects. In the
present study, we were interested whether O-1602 pro-
duces antitumorigenic effects in colon cancer cells and
whether it could reduce tumorigenesis in the colon in vivo.
Methods
We used the cell lines HT-29 and SW480 to study the
effect of O-1602 on viability and apoptosis in cancer
cells. A mouse model of colitis-associated colon cancer
was employed to study the effect of O-1602 on tumor
growth in vivo.
Results
Viability of HT-29 and SW480 cells was decreased and
apoptosis was promoted by O-1602 in a concentration-
dependent manner (0.1–10 µM). In the mouse model,
treatment with O-1602 (3 mg/kg, i.p., 12x, every second
day during a period of 3 weeks) reduced tumor area by
50% and tumor incidence by 30%. Histological scoring
showed a significant decrease in tumor load. In tumor tis-
sue, O-1602 decreased levels of phosphorylated activator
of transcription factor 3 (pSTAT3) by 50% and tumor
necrosis factor alpha (TNF-a) by around 45%. Treatment
with O-1602 led to a ten-fold increase in the expression of
the tumor suppressor p53.
Conclusions
O-1602 exerts antitumorigenic effects by targeting colon
cancer cells as well as proinflammatory pathways known
to promote colitis-associated tumorigenesis, thus providing
a novel insight into antitumorigenic mechanisms of atypi-
cal cannabinoids. As O-1602 is free of central sedation, it
could be an interesting compound for the treatment of
colon and possibly other cancers.
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